Study participants received dronabinol (0, 120mg/day and 240mg/day) for 12 consecutive days
in a randomized order. During each dronabinol maintenance period they were able to
self-administer active or placebo cannabis using either a progressive ratio schedule or
choice between cannabis and monetary alternative.